Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
Antivasoproliferative therapy is a revolutionary trend in the treatment of neovascular age-related macular degeneration (nAMD), as it is aimed at blocking growth factors of the newly formed vessels. Currently, two anti-VEGF drugs are registered for ophthalmological use, and the search for new molecu...
Saved in:
| Main Author: | R. R. Fayzrakhmanov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2019-06-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01) -
Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration
by: N. S. Zhajvoronok, et al.
Published: (2019-12-01) -
Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01) -
Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study
by: Mekala Shellvarajah, et al.
Published: (2025-04-01) -
Incidence and Clinical Practice of Myopic Macular Neovascularization: A Nationwide Population-Based Cohort Study
by: Masahiro Akada, MD, et al.
Published: (2025-11-01)